Assembly Biosciences, Inc. ASMB
Price alert —
Sign in to get a one-time email the moment ASMB crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ASMB
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -110.5% | -138.4% |
| 2025-12-31 | $0.0B | $0.0B | $0.0B | $0.0B | 52.0% | 46.6% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -85.2% | -100.9% |
| 2025-06-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -105.9% | -115.2% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -93.6% | -105.5% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ASMB vs peers
Line ASMB up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ASMB
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.54 | -0.64 | +15.2% | -3.9% |
| 2026-03-19 | 2.48 | -0.85 | +392.9% | +3.5% |
| 2025-11-10 | -0.72 | -0.65 | -10.2% | +3.3% |
| 2025-08-06 | -1.33 | -1.73 | +23.1% | +9.2% |
| 2025-05-08 | -1.17 | -1.60 | +26.9% | +5.0% |
| 2025-03-20 | -1.57 | -1.75 | +10.3% | +3.0% |
| 2024-11-07 | -1.51 | -1.85 | +18.4% | -4.1% |
| 2024-08-08 | -1.98 | -2.23 | +11.2% | -2.8% |
| 2024-05-08 | -1.66 | -3.23 | +48.6% | +1.2% |
| 2024-03-28 | -1.74 | -3.18 | +45.3% | -3.0% |
| 2023-11-08 | -3.24 | -2.76 | -17.4% | -11.8% |
| 2023-08-09 | -3.84 | -3.18 | -20.8% | +0.9% |
| 2023-05-04 | -4.44 | -4.68 | +5.1% | -1.0% |
| 2023-03-22 | -5.52 | -5.76 | +4.2% | -8.6% |
| 2022-11-08 | -5.76 | -6.48 | +11.1% | -4.4% |
| 2022-08-09 | -6.12 | -5.76 | -6.2% | +0.5% |
| 2022-05-12 | -5.76 | -4.88 | -18.0% | +6.2% |
| 2022-03-11 | -4.88 | -6.39 | +23.6% | -3.3% |
| 2021-11-04 | -4.92 | -7.14 | +31.1% | -1.9% |
| 2021-08-05 | -6.60 | -8.25 | +20.0% | +0.3% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ASMB ★ | $1B | 335.1 | -12.7 | 7.5 | -15.0 | 2.1 | 8.8% | -12.8% | — | -3.12% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 68.03%
| Holder | Shares | % out |
|---|---|---|
| Gilead Sciences Inc | 4,505,391 | 28.35% |
| Farallon Capital Management LLC | 1,227,590 | 7.72% |
| RA Capital Management, L.P. | 1,020,410 | 6.42% |
| Commodore Capital Lp | 1,000,000 | 6.29% |
| Janus Henderson Group PLC | 849,309 | 5.34% |
| Paradigm Biocapital Advisors LP | 665,251 | 4.19% |
| Vanguard Capital Management LLC | 490,447 | 3.09% |
| Parkman Healthcare Partners LLC | 411,227 | 2.59% |
| Point72 Asset Management, L.P. | 344,105 | 2.17% |
| Blackstone Inc | 296,855 | 1.87% |
Insider activity · 90d
7 buys / 1 sells · ratio 7.0 · Finnhub
- Bjorkquist Jeanette M SELL 14,560 @ $23.25
- McHutchison John G BUY 8,000
- Mahony Susan BUY 8,000
- Johnson-Pratt Lisa BUY 8,000
- Houghton Michael BUY 8,000
- Consylman Gina BUY 8,000
- ALTIG ANTHONY E BUY 8,000
- GILEAD SCIENCES, INC. BUY 4,977,089 @ $26.50
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 4 | 2026-06-05 | 4 | view · |
| 8-K | 2026-06-05 | 8-K | view · |
| 4 | 2026-05-27 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | view · |
| 8-K | 2026-05-26 | 8-K | view · |
| 8-K | 2026-05-22 | 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-22 | DEF 14A | view · |
| 4 | 2026-03-31 | 4 | view · |
| 4 | 2026-03-31 | 4 | view · |
| 4 | 2026-03-31 | 4 | view · |
| 4 | 2026-03-31 | 4 | view · |
| 4 | 2026-03-31 | 4 | view · |
| 8-K | 2026-03-30 | 8-K | view · |
| 10-K | 2026-03-19 | 10-K | view · |
| 8-K | 2026-03-19 | 8-K | view · |
| 8-K | 2025-12-08 | 8-K | view · |
| 10-Q | 2025-11-10 | 10-Q | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 4 | 2025-10-03 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | view · |
| 8-K | 2025-08-11 | 8-K | view · |
| 8-K | 2025-08-08 | 8-K | view · |
| 10-Q | 2025-08-06 | 10-Q | view · |
| 8-K | 2025-08-06 | 8-K | view · |
| 8-K | 2025-06-25 | 8-K | view · |
| 4 | 2025-06-17 | 4 | view · |
| 8-K | 2025-06-09 | 8-K | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 4 | 2025-06-09 | 4 | view · |
| 10-Q | 2025-05-08 | 10-Q | view · |
| 8-K | 2025-05-08 | 8-K | view · |
| DEF 14A | 2025-04-23 | DEF 14A | view · |
| 4 | 2025-04-15 | 4 | view · |
| 4 | 2025-04-01 | 4 | view · |
| 4 | 2025-04-01 | 4 | view · |
| 4 | 2025-04-01 | 4 | view · |
| 4 | 2025-04-01 | 4 | view · |
| 4 | 2025-04-01 | 4 | view · |
| 10-K | 2025-03-20 | 10-K | view · |
| 8-K | 2025-03-20 | 8-K | view · |
| 8-K | 2025-02-20 | 8-K | view · |
| 8-K | 2025-01-03 | 8-K | view · |
| 4 | 2024-12-31 | 4 | view · |
| 8-K | 2024-12-26 | 8-K | view · |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Options picks · ASMB
ITM + OTM ideas from the latest scanLoading…
Congress trades · ASMB
STOCK Act disclosuresLoading…
SEC filings & insiders · ASMB
EDGAR · liveLoading…
Holders · ASMB
Institutions & insider activityLoading…